Abstract
The main goal of therapy for Parkinson's disease (PD) is to correct dopamine deficiency in the nigrostriatal system. Levodopa preparations and dopamine receptor agonists (DRAs) that are prescribed with regards to patient age and disease severity are mainly used now. Notwithstanding the fact that levodopa preparations are the gold standard of therapy, their long-term use gives rise to complications as motor fluctuations and drug-induced dyskinesias. The currently available DRAs are the drugs of choice for the therapy of early-stage PD as they are as effective as levodopa preparations. In extensive-stage PD, DRAs are used to enhance the therapy and correction of developed motor fluctuations and dyskinesias. Pramipexole is one of the most commonly used representatives of non-ergoline DRAs. The paper analyzes the efficacy of the medication used as both monotherapy and part of combined therapy, its effect on tremor and depression in PD. A novel extended-release formulation of pramipexole is considered separately. Both immediate- and extended-release pramipexole formulations contain the same active ingredient and have the same dopamine-receptor interaction profile, but differ in the tablet release rate of the active ingredient. The advantages of the novel formulation are its more steady-state plasma concentration and 24-hour action, which ensures continuous dopaminergic stimulation of postsynaptic receptors to prevent and treat already developed motor complications. The once-daily extended-release formulation of the drug makes its treatment regimen easier and patient compliance higher.
Highlights
Основной целью терапии болезни Паркинсона (БП) является коррекция дефицита дофамина в нигростриарной системе
Levodopa preparations and dopamine receptor agonists (DRAs) that are prescribed with regards to patient age and disease severity are mainly used
Notwithstanding the fact that levodopa preparations are the gold standard of therapy, their long-term use gives rise to complications as motor fluctuations and drug-induced dyskinesias
Summary
Основной целью терапии болезни Паркинсона (БП) является коррекция дефицита дофамина в нигростриарной системе. У пациентов на развернутых стадиях болезни, получающих препараты леводопы, добавление АДР позволило уменьшить их дозу и, следовательно, снизить риск развития и выраженность моторных флуктуаций и дискинезий. В дальнейшем было показано, что данный класс препаратов при использовании в виде монотерапии на начальных стадиях заболевания по эффективности не уступает препаратам леводопы и позволяет отсрочить их назначение.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have